Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4921 AL 4935

Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease

Arai H, Umemura K, Ichimiya Y, Iseki E, Eto K, Miyakawa K, Kirino E, Shibata N, Baba H, Tsuchiwata S.

Geriatr Gerontol Int. 2016 May;16(5):644-50. doi: 10.1111/ggi.12516. Epub 2015 Jun 4.

The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients

Zhang N, Wei C, Du H, Shi FD, Cheng Y.

Dement Geriatr Cogn Disord. 2015;40(1-2):85-93. doi: 10.1159/000430808. Epub 2015 Jun 5.

Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers

Riepe M, Weinman J, Osae-Larbi J, Mulick Cassidy A, Knox S, Chaves R, Müller B.

Dement Geriatr Cogn Disord. 2015;40(1-2):107-19. doi: 10.1159/000381894. Epub 2015 Jun 5.

Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials

Zis P, Mitsikostas DD.

J Neurol Sci. 2015 Aug 15;355(1-2):94-100. doi: 10.1016/j.jns.2015.05.029. Epub 2015 May 28.

Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial

Zhang Y, Lin C, Zhang L, Cui Y, Gu Y, Guo J, Wu D, Li Q, Song W.

PLoS One. 2015 Jun 15;10(6):e0130353. doi: 10.1371/journal.pone.0130353. eCollection 2015.

Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan

Arai H, Sumitomo K, Sakata Y, Daidoji K, Takase T, Toyoda T.

Psychogeriatrics. 2016 Mar;16(2):107-15. doi: 10.1111/psyg.12130. Epub 2015 Jun 26.

Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials

Soejitno A, Tjan A, Purwata TE.

CNS Drugs. 2015 Jun;29(6):487-502. doi: 10.1007/s40263-015-0257-8.

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans

Aisen PS, Petersen RC, Donohue M, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):734-9. doi: 10.1016/j.jalz.2015.05.005.

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)

Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J, Carrillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter WZ, Siemers E, Schwarz AJ.

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001.

Namzaric--a combination of 2 old drugs for Alzheimer's disease

Med Lett Drugs Ther. 2015 Jul 20;57(1473):105-6.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease

Kalra J, Khan A.

Eur J Pharmacol. 2015 Oct 5;764:571-581. doi: 10.1016/j.ejphar.2015.07.043. Epub 2015 Jul 21.

Current and novel therapeutic molecules and targets in Alzheimer's disease

Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K, Gupta N, Nair P, Tripathi T, Kumar A.

J Formos Med Assoc. 2016 Jan;115(1):3-10. doi: 10.1016/j.jfma.2015.04.001. Epub 2015 Jul 26.

What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?

Becker RE, Seeman MV, Greig NH, Lahiri DK.

Lancet Psychiatry. 2015 Aug;2(8):756-764. doi: 10.1016/S2215-0366(15)00214-X.

Current thinking on the mechanistic basis of Alzheimer's and implications for drug development

Ising C, Stanley M, Holtzman DM.

Clin Pharmacol Ther. 2015 Nov;98(5):469-71. doi: 10.1002/cpt.200. Epub 2015 Sep 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias